- Home
- DVAX vs MSEX Comparison
DVAX vs MSEX Comparison
Compare DVAX & MSEX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DVAX
- MSEX
- Stock Information
- Founded
- DVAX 1996
- MSEX 1897
- Country
- DVAX United States
- MSEX United States
- Employees
- DVAX N/A
- MSEX N/A
- Industry
- DVAX Biotechnology: Pharmaceutical Preparations
- MSEX Water Supply
- Sector
- DVAX Health Care
- MSEX Utilities
- Exchange
- DVAX Nasdaq
- MSEX Nasdaq
- Market Cap
- DVAX 1.2B
- MSEX 963.9M
- IPO Year
- DVAX 2004
- MSEX N/A
- Fundamental
- Price
- DVAX $10.15
- MSEX $54.71
- Analyst Decision
- DVAX Buy
- MSEX Buy
- Analyst Count
- DVAX 4
- MSEX 4
- Target Price
- DVAX $26.50
- MSEX $61.00
- AVG Volume (30 Days)
- DVAX 1.7M
- MSEX 135.5K
- Earning Date
- DVAX 11-06-2025
- MSEX 10-30-2025
- Dividend Yield
- DVAX N/A
- MSEX 2.49%
- EPS Growth
- DVAX N/A
- MSEX 17.05
- EPS
- DVAX N/A
- MSEX 2.41
- Revenue
- DVAX $316,268,000.00
- MSEX $195,831,000.00
- Revenue This Year
- DVAX $23.23
- MSEX $5.46
- Revenue Next Year
- DVAX $16.57
- MSEX $8.74
- P/E Ratio
- DVAX N/A
- MSEX $22.68
- Revenue Growth
- DVAX 26.66
- MSEX 11.91
- 52 Week Low
- DVAX $9.20
- MSEX $48.18
- 52 Week High
- DVAX $14.63
- MSEX $70.73
- Technical
- Relative Strength Index (RSI)
- DVAX 52.11
- MSEX 57.02
- Support Level
- DVAX $9.95
- MSEX $51.90
- Resistance Level
- DVAX $10.35
- MSEX $54.31
- Average True Range (ATR)
- DVAX 0.29
- MSEX 1.17
- MACD
- DVAX 0.08
- MSEX 0.13
- Stochastic Oscillator
- DVAX 75.00
- MSEX 82.28
About DVAX Dynavax Technologies Corporation
Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.
About MSEX Middlesex Water Company
Middlesex Water Co owns and operates regulated water utility and wastewater systems in the U.S. The firm operates in the eastern states of New Jersey, Delaware, and Pennsylvania. The company has two operating segments, Regulated and Non-Regulated. The regulated business includes collecting and distributing water to residential, commercial, industrial, and fire protection consumers. The non-regulated business includes contract services for the operation of private water and wastewater systems. The majority of the company's revenue is derived from the Regulated segment and from residential customers.